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background: Anacetrapib is a cholesteryl ester transfer protein inhibitor that has previously been shown to be well tolerated, reduce low-density 
lipoprotein cholesterol (LDL-C) and raise high-density lipoprotein cholesterol (HDL-C) in patients with or at high risk for coronary heart disease in the 
DEFINE base study.
methods: Patients who had been randomized to treatment with anacetrapib 100 mg/day or placebo in the 76-week base study continued on 
the same treatment during the 2-year extension study (n=803). Endpoints included lipid measures, safety variables, pre-specified adjudicated 
cardiovascular events, and plasma anacetrapib levels.
results: In patients who entered the 2-year extension study, treatment with anacetrapib (n=370) during the 2-year extension was well tolerated 
with a safety profile similar to patients on placebo (n=433). No clinically important abnormalities in liver enzymes, blood pressure, electrolytes, 
and adverse experiences were observed during the extension. Anacetrapib reduced Friedewald-calculated LDL-C by 39.9% and increased HDL-C by 
153.3%, compared to placebo. Geometric mean plasma concentrations of anacetrapib did not appear to increase beyond week 40 for patients in 
the 2-year extension of the DEFINE study. The apparent steady-state mean plasma trough anacetrapib concentration was ~640 nM.
conclusion: During the 2-year extension study, treatment with anacetrapib was well tolerated with durable lipid-modifying effects on LDL-C and 
HDL-C.
   
